Would you like to receive the #1 rated penny stock newsletter?
If you answered yes, then receiving Aim High Profits’ Penny Stock Alerts will help guide you to some of the biggest and most profitable trading alerts and techniques that are proven to bring in the “big bucks“.
And now….The Stock to Own for 2012…..The Stock to Own in the Stock Market Today……
Finally – A Christmas Gift We Can All Be Thankful For!!! Get Out there today and Grab it!!!!
The number of believers in cancer vaccines is growing, and the money is following – GNBT might have stumbled upon the CURE FOR BREAST CANCER!
Yes, that’s right and you can even read about it in Newsweek if you haven’t already. Read about it here.
Yesterday, GNBT announced that Bloomberg Television is scheduled to air a segment on the immunotherapeutic breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc. (Read more)
Today, GNBT announced that the Bloomberg Television segment on the Antigen Express breast cancer vaccine did not air yesterday as originally scheduled (and announced in Bloomberg Television’s December 16, 2011 promotional spot). The Company will provide a further update once representatives of Bloomberg Television advise as to a rescheduled air date and time.
The biotechnology industry has been a strong performer in 2011 as mergers and acquisitions and favorable legislation have propped up the sector. The domestic biotechnology industry has tapped into only a fraction of its several potential applications and is expected to grow to $146.2 billion in 2016, from an estimated $92.4 billion in 2011.
GNBT could be set up for a HUGE PAY OUT!!! Imagine what kind of money will be thrown at GNBT should a Giant take them over with this new vaccine for Breast Cancer!
- GNBT is trading above both its MA(50) and MA(200)
- GNBT Current price is 0.175
- GNBT has been as high as 0.70 in the last 2 years
Positive interim results from their study were recently presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). Final Phase 2 results are expected in 2012.
Imagine the kind of money the Giants will be throwing at GNBT come 2012 when they complete phase 2…..
- About 1 in 8 U.S. women (just under 12%) will develop invasive breast cancer over the course of her lifetime.
- In 2011, an estimated 230,480 new cases of invasive breast cancer were expected to be diagnosed in women in the U.S., along with 57,650 new cases of non-invasive (in situ) breast cancer.
- About 2,140 new cases of invasive breast cancer were expected to be diagnosed in men in 2011. A man’s lifetime risk of breast cancer is about 1 in 1,000.
- From 1999 to 2005, breast cancer incidence rates in the U.S. decreased by about 2% per year. The decrease was seen only in women aged 50 and older. One theory is that this decrease was partially due to the reduced use of hormone replacement therapy (HRT) by women after the results of a large study called the Women’s Health Initiative were published in 2002. These results suggested a connection between HRT and increased breast cancer risk.
- About 39,520 women in the U.S. were expected to die in 2011 from breast cancer, though death rates have been decreasing since 1990 — especially in women under 50. These decreases are thought to be the result of treatment advances, earlier detection through screening, and increased awareness.
- For women in the U.S., breast cancer death rates are higher than those for any other cancer, besides lung cancer.
- Besides skin cancer, breast cancer is the most commonly diagnosed cancer among American women. Just under 30% of cancers in women are breast cancers.
- White women are slightly more likely to develop breast cancer than African-American women. However, in women under 45, breast cancer is more common in African-American women than white women. Overall, African-American women are more llkely to die of breast cancer. Asian, Hispanic, and Native-American women have a lower risk of developing and dying from breast cancer.
- In 2011, there were more than 2.6 million breast cancer survivors in the US.
- A woman’s risk of breast cancer approximately doubles if she has a first-degree relative (mother, sister, daughter) who has been diagnosed with breast cancer. About 15% of women who get breast cancer have a family member diagnosed with it.
- About 5-10% of breast cancers can be linked to gene mutations (abnormal changes) inherited from one’s mother or father. Mutations of the BRCA1 and BRCA2 genes are the most common. Women with these mutations have up to an 80% risk of developing breast cancer during their lifetime, and they are more likely to be diagnosed at a younger age (before menopause). An increased ovarian cancer risk is also associated with these genetic mutations.
- In men, about 1 in 10 breast cancers are believed to be due to BRCA2 mutations, and even fewer cases to BRCA1 mutations.
- About 85% of breast cancers occur in women who have no family history of breast cancer. These occur due to genetic mutations that happen as a result of the aging process and life in general, rather than inherited mutations.
- The most significant risk factors for breast cancer are gender (being a woman) and age (growing older).
About Generex Biotechnology Corp.:
GNBT, a development stage company, together with its subsidiary, engages in the research and development of drug delivery systems and technologies for metabolic and immunological diseases. GNBT primarily focuses on its proprietary technology for the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator. GNBT also engages in the research and development of technologies and immunomedicines for the treatment of malignant, infectious, autoimmune, and allergic diseases. GNBT‘s products include Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity using hand-held aerosol spray applicator, known as RapidMist, for the treatment of Type-1 and Type-2 diabetes; over-the-counter glucose sprays, including Glucose RapidSpray, a fat-free low-calorie glucose formulation; and MetControl, a Metformin medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity. GNBT also develops various buccal morphine and fentanyl products, other buccal products, and immunomedicine technology and products. GNBT sells its products through retail stores and independent pharmacies primarily in the United States and Canada.
GNBT is a MUST ADD to your Stock Watch List!!!!
***Reminder: never chase stocks that gap at the open and always protect your profits!
AND AS ALWAYS…………..
- Do your own research.
- Trade Responsibly.
- Verify everything.
- Do not use market orders to enter a position, use limit orders.
- Have a System That fits You.
- If a Stock Gaps Open, Look for Pullbacks to Enter.
- Plan a Trade and Trade a Plan.
- Always use stop loss orders to protect yourself.
- Positive Self- Belief.
- Keep trading as Part of a Balanced life.
- If a stock breaks below our alert price GET OUT. Do not wait.
- View Trading as a Score in Points and Not In Money:
- Always take your profits whenever you can. Do Not Be Greedy.
- Work Hard at Learning How to Trade Properly and Keep Working.
- Do something to make someone else’s life better today.
Good luck in making the best penny stock picks.